Taken together, professors suggested that serum IL-22 levels could be a negative prognostic indicator in patients with HBV-related HCC, and that IL-22 should not be used in patients with pre-cancerous cirrhosis or liver cancer. Here, IL22 is linked to Cirrhosis.